Skip to main content

Policy Brief on Human Papillomavirus Vaccination in Swiss General Practice

Chronic infections with Human Papillomavirus (HPV) are a major cause of anogenital cancer. Associated diseases are related with high mortality and morbidity. A highly effective vaccine is available and recommended in Switzerland for all boys and girls between the ages of 11 and 26.
However, vaccination rates in Switzerland have been low for years.

For young adults, general practitioners become the primary point of contact for health issues. This creates a unique opportunity to identify previously unvaccinated young adults and offer catch-up vaccination. Nevertheless, HPV vaccinations are rare in general practice and there is no large increase in vaccination rates among young adults. There are numerous reasons for this evidence-performance gap.




The main objective of this policy brief and stakeholder dialogue is to critically discuss and possibly improve the challenges of closing the evidence-performance gap on HPV vaccination in Swiss General Practice.

Andreas Plate, author of the Policy Brief

Author: Andreas Plate

Institution: University of Zurich


If you are interested in the topic please contact us.

Policy Briefs & Stakeholder Dialogues

Each partner institution of the Swiss Learning Health System (SLHS) is working on a specific topic that will lead to policy briefs and stakeholder dialogues.

Cookies information

We use cookies to make our website more user-friendly and to compile anonymous statistics. No personal data is stored. Privacy policy »